Publications by authors named "P E Albrecht"
Purpose: To identify baseline clinical predictors of visual outcomes six months after acute optic neuritis using data from our completed clinical neuroprotection trial (TONE study).
Design: Secondary analysis of data from the TONE study cohort (NCT01962571).
Subjects: Total of 103 patients presenting within 10 days of a first episode of acute unilateral optic neuritis as a clinically isolated syndrome with baseline high contrast visual acuity (HCVA) < 20/40 Snellen (logMAR 0.
Article Synopsis
- The study examined cognitive symptoms in individuals infected with SARS-CoV-2, finding that while most had mild respiratory symptoms, many also experienced cognitive issues like attention and memory deficits.
- At baseline, those with SARS-CoV-2 showed higher fatigue levels compared to those who tested negative, but improvements in cognitive scores were noted in both groups over time.
- Ultimately, the research highlights that even mild cases of COVID-19 can be linked to increased fatigue and cognitive challenges, reinforcing previous findings.
The versatility of somatosensation arises from heterogeneous dorsal root ganglion (DRG) neurons. However, soma transcriptomes of individual human (h)DRG neurons-critical information to decipher their functions-are lacking due to technical difficulties. In this study, we isolated somata from individual hDRG neurons and conducted deep RNA sequencing (RNA-seq) to detect, on average, over 9,000 unique genes per neuron, and we identified 16 neuronal types.
View Article and Find Full Text PDFBackground: Optic neuritis (ON) is a common manifestation of multiple sclerosis (MS) and myelin-oligodendrocyte-glycoprotein IgG-associated disease (MOGAD). This study evaluated the applicability of optical coherence tomography (OCT) for differentiating between both diseases in two independent cohorts.
Methods: One hundred sixty two patients from seven sites underwent standard OCT and high-contrast visual acuity (HCVA) testing at least 6 months after first ON.